<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19424" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Autosomal Recessive Polycystic Kidney Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Subramanian</surname>
            <given-names>Surabhi</given-names>
          </name>
          <aff>IWK Health Centre</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahmad</surname>
            <given-names>Tahani</given-names>
          </name>
          <aff>IWK Health Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Surabhi Subramanian declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tahani Ahmad declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19424.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Autosomal recessive polycystic kidney disease (ARPKD) is a rare genetic disorder primarily affecting the kidneys and liver. Clinicians should recognize early signs such as enlarged, echogenic kidneys in utero or during infancy. ARPKD most commonly results from mutations in <italic toggle="yes">PKHD1</italic>, causing renal cysts and congenital hepatic fibrosis early in life. About half of the patients with ARPKD develop end-stage renal failure requiring renal replacement therapy (dialysis or kidney transplantation) within the first&#x000a0;2 decades of life. In addition, hepatic function must be closely followed, as portal hypertension, splenomegaly, and cholangitis are common, especially in older patients.</p>
        <p>This course provides in-depth insights into the diverse clinical presentations, diagnostic modalities, and management strategies for this rare genetic disorder. Clinicians gain proficiency in recognizing early signs, conducting genetic testing, and implementing a comprehensive,&#x000a0;interprofessional approach to patient care.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between ARPKD and other renal disorders, recognizing distinctive clinical and genetic features to facilitate accurate diagnosis and tailored management.</p></list-item><list-item><p>Implement proactive management strategies for ARPKD, focusing on multidisciplinary care to address renal and hepatic complications, ensuring optimal patient outcomes.</p></list-item><list-item><p>Apply evidence-based interventions and therapeutic approaches for ARPKD, considering individual patient needs and adapting strategies to mitigate disease progression.</p></list-item><list-item><p>Collaborate with geneticists, nephrologists, hepatologists, urologists, surgeons, genetic counselors, and other relevant specialists to create a cohesive and comprehensive care plan for ARPKD patients, addressing both renal and hepatic aspects.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19424&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19424">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19424.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Autosomal recessive polycystic kidney disease is a rare genetic disorder primarily affecting the kidneys and liver. Clinicians should recognize early signs such as enlarged, echogenic kidneys in utero or during infancy. ARPKD most commonly results from mutations in&#x000a0;<italic toggle="yes">PKHD1</italic>, causing renal cysts and congenital hepatic fibrosis early in life. About half of the patients with ARPKD develop end-stage renal failure requiring renal replacement therapy (dialysis or kidney transplantation) within the first&#x000a0;2 decades of life. In addition, hepatic function must be closely followed, as portal hypertension, splenomegaly, and cholangitis are common, especially in older patients.</p>
        <p>The 2&#x000a0;varieties of polycystic kidney disease (PKD) based on inheritance are the relatively common autosomal dominant and the much rarer autosomal recessive types.<xref ref-type="bibr" rid="article-19424.r1">[1]</xref> These&#x000a0;2 forms have distinct clinical and genetic features.<xref ref-type="bibr" rid="article-19424.r1">[1]</xref></p>
        <p><bold>Autosomal dominant polycystic kidney disease</bold> (ADPKD), previously called adult polycystic kidney disease, is a multisystem progressive cystic disorder primarily affecting the kidneys. It is characterized by bilateral renal cysts, which progressively lead to fibrosis, architectural distortion, hypertension, and progressive renal failure, typically becoming symptomatic starting at about 30 years of age.<xref ref-type="bibr" rid="article-19424.r1">[1]</xref><xref ref-type="bibr" rid="article-19424.r2">[2]</xref><xref ref-type="bibr" rid="article-19424.r3">[3]</xref>&#x000a0;In adult patients, it is the most frequent genetic cause of renal failure and end-stage kidney disease. Please see the companion StatPearls reference, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/27399">Autosomal Dominant Polycystic Kidney Disease</ext-link>," for further information.<xref ref-type="bibr" rid="article-19424.r3">[3]</xref>&#x000a0;</p>
        <p><bold>Autosomal recessive polycystic kidney disease</bold> (ARPKD) primarily involves the kidney and liver. Historically referred to&#x000a0;as&#x000a0;infantile polycystic kidney disease, it can present&#x000a0;in neonatal, infantile, juvenile, or even adult populations. Hence, the old nomenclature of&#x000a0;adult&#x000a0;and infantile polycystic kidney disease&#x000a0;is not used&#x000a0;anymore.<xref ref-type="bibr" rid="article-19424.r4">[4]</xref>&#x000a0;</p>
        <p>ARPKD is characterized by renal distal tubule and collecting duct cyst formation, hepatic biliary&#x000a0;duct ectasia/malformation, and fibrosis involving both the liver and kidneys.<xref ref-type="bibr" rid="article-19424.r5">[5]</xref>&#x000a0;</p>
        <p>ARPKD is a ciliopathy and presents with cysts along the distal renal tubules and collecting ducts, compared to ADPKD, where the cysts can develop anywhere along the nephron.&#x000a0;Cysts in ARPKD are mostly microcystic in early childhood, may develop calcifications, and can produce renal calculi. In older children, the cysts become larger and concentrated in the renal medulla.</p>
        <p>The clinical presentation of ARPKD varies significantly, with some patients diagnosed at a young age having more severe symptoms than those diagnosed when older.<xref ref-type="bibr" rid="article-19424.r6">[6]</xref>&#x000a0;ARPKD is always associated with liver bile duct malformations, both intrahepatic and extrahepatic. Liver manifestations vary from mild cholestasis to hepatic fibrosis, portal vein hypertension, esophageal varices, cholangitis, and cirrhosis.<xref ref-type="bibr" rid="article-19424.r7">[7]</xref></p>
        <p>A key factor in understanding the presentations of ARPKD is that 30% to 40% of affected neonates have been reported to die perinatally, usually due to respiratory distress from pulmonary hypoplasia from oligohydramnios related to decreased fetal urine production.<xref ref-type="bibr" rid="article-19424.r8">[8]</xref><xref ref-type="bibr" rid="article-19424.r9">[9]</xref>&#x000a0;Improved neonatal care has reduced the newborn mortality rate to just 20%.<xref ref-type="bibr" rid="article-19424.r10">[10]</xref></p>
        <p>Survival rates are 85% and 82% for those who survive the perinatal period at 1 and 10 years, respectively.<xref ref-type="bibr" rid="article-19424.r11">[11]</xref><xref ref-type="bibr" rid="article-19424.r12">[12]</xref>&#x000a0;Of note, some of the perinatal data may have been derived from older studies conducted prior to technical advances in neonatal intensive care, reducing perinatal mortality to about 20% within the first month of life.<xref ref-type="bibr" rid="article-19424.r7">[7]</xref></p>
      </sec>
      <sec id="article-19424.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There is considerable variability in the phenotypic expression of ARPKD. More than 90% of ARPKD cases are caused by mutations in the <italic toggle="yes">PKHD1</italic> gene on chromosome 6p12.<xref ref-type="bibr" rid="article-19424.r13">[13]</xref>&#x000a0;Its function is to regulate the production of fibrocystin (polyductin), which is involved in cellular adhesion, ciliary function, and cell proliferation in the kidney and liver.<xref ref-type="bibr" rid="article-19424.r14">[14]</xref><xref ref-type="bibr" rid="article-19424.r15">[15]</xref><xref ref-type="bibr" rid="article-19424.r16">[16]</xref></p>
        <p>There is evidence of extensive alternative splicing of this gene.&#x000a0;A critical amount of full-length protein secreted by this gene is responsible for the normal function&#x000a0;of tubular epithelium. More recently, DAZ-interacting zinc finger protein 1-like<italic toggle="yes"> (</italic><italic toggle="yes">DZIP1L)</italic> has been implicated in some cases of ARPKD, but it is extremely rare.<xref ref-type="bibr" rid="article-19424.r7">[7]</xref></p>
        <p>Patients with tuberous sclerosis have mutations in&#x000a0;<italic toggle="yes">TSC1</italic>&#x000a0;and&#x000a0;<italic toggle="yes">TSC2.&#x000a0;</italic>These genes are localized to chromosome 16, the same as&#x000a0;<italic toggle="yes">PKD1.&#x000a0;</italic>Patients with tuberous sclerosis often have an early onset of PKD and present similarly to ARPKD.</p>
      </sec>
      <sec id="article-19424.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>ARPKD is one of the most common causes of heritable, infantile cystic renal disease. Despite that, it is found in only 1 in 20,000 to 40,000 live births.<xref ref-type="bibr" rid="article-19424.r17">[17]</xref>&#x000a0;In nonisolated populations, this suggests a carrier frequency of about 1 in 70.<xref ref-type="bibr" rid="article-19424.r5">[5]</xref><xref ref-type="bibr" rid="article-19424.r10">[10]</xref></p>
        <p>There is no gender, ethnic, or racial predilection. Patients who are heterozygous for ARPKD can show mild variations of polycystic kidney or hepatic cystic disease.<xref ref-type="bibr" rid="article-19424.r11">[11]</xref>&#x000a0;The number of children with early onset autosomal dominant polycystic kidney disease is comparable to the number with ARPKD, which can make differentiation difficult in the pediatric age group.<xref ref-type="bibr" rid="article-19424.r18">[18]</xref><xref ref-type="bibr" rid="article-19424.r19">[19]</xref></p>
      </sec>
      <sec id="article-19424.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The gene responsible for most ARPKD cases is<italic toggle="yes">&#x000a0;</italic>Polycystic Kidney and Hepatic Disease 1<italic toggle="yes">&#x000a0;</italic>(<italic toggle="yes">PHKD1)</italic><italic toggle="yes">.&#x000a0;</italic>The protein encoded by <italic toggle="yes">PKHD1</italic> is fibrocystin (polyductin), a membrane protein found mainly in the distal tubules of the kidneys and biliary ducts of the liver.<xref ref-type="bibr" rid="article-19424.r20">[20]</xref> The exact function of this protein is somewhat uncertain, but it is thought to be involved in cellular adhesion, ciliary function, and cell proliferation.<xref ref-type="bibr" rid="article-19424.r14">[14]</xref><xref ref-type="bibr" rid="article-19424.r15">[15]</xref><xref ref-type="bibr" rid="article-19424.r16">[16]</xref></p>
        <p>Defects of&#x000a0;<italic toggle="yes">PKHD1</italic>&#x000a0;also&#x000a0;cause embryologic ductal plate malformations, leading to congenital hepatic fibrosis. Eventually, this results in variable dilatation in the intrahepatic and extrahepatic bile ducts (Caroli disease).<xref ref-type="bibr" rid="article-19424.r21">[21]</xref> Associated clinical manifestations are primarily portal hypertension, splenomegaly, hepatic fibrosis, and cholangitis.<xref ref-type="bibr" rid="article-19424.r11">[11]</xref><xref ref-type="bibr" rid="article-19424.r21">[21]</xref>&#x000a0;See&#x000a0;the&#x000a0;companion Statpearls reference, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/18956">Caroli Syndrome</ext-link>," for more information.<xref ref-type="bibr" rid="article-19424.r11">[11]</xref><xref ref-type="bibr" rid="article-19424.r21">[21]</xref></p>
        <p>Mammalian targets of rapamycin (mTOR) and cyclic AMP (cAMP) are&#x000a0;2 of these pathways being studied.<xref ref-type="bibr" rid="article-19424.r11">[11]</xref> Animal ARPKD models testing epithelial growth receptor blockers and epithelial enzymes have shown promising results, which may pave the way for therapeutic interventions at the cellular level.<xref ref-type="bibr" rid="article-19424.r22">[22]</xref></p>
        <p>The pathogenesis of ARPKD is characterized by circumferential proliferation of epithelial cells, which predominantly affects the collecting ducts in renal tubules.<xref ref-type="bibr" rid="article-19424.r23">[23]</xref> The primary pathology involves abnormal epithelial cell proliferation, which forms cysts that detach from the tubule once they reach a certain size.<xref ref-type="bibr" rid="article-19424.r23">[23]</xref> The abnormal proliferation of renal tubule epithelium causes them to lose their normal physiological function, and they fill with fluid from transepithelial secretion.<xref ref-type="bibr" rid="article-19424.r23">[23]</xref></p>
        <p>The fluid is rich in epithelial growth factors, which leads to further proliferation of epithelial cells. This leads to extracellular matrix deposition and increased cytokines, growth factors, and inflammation. All these factors lead to renal fibrosis, proximal tubule apoptosis, and loss of kidney function.<xref ref-type="bibr" rid="article-19424.r11">[11]</xref>&#x000a0;Later in the disease, the kidney becomes massively enlarged with macrocysts and interstitial fibrosis&#x02014; similar to the presentation of ADPKD.<xref ref-type="bibr" rid="article-19424.r11">[11]</xref>&#x000a0;</p>
        <p>Defects of the&#x000a0;<italic toggle="yes">PKHD1</italic>&#x000a0;gene also&#x000a0;cause embryologic ductal plate malformation, leading to congenital hepatic fibrosis. Eventually, this results in variable dilatation in the intrahepatic and extrahepatic bile ducts (Caroli disease).<xref ref-type="bibr" rid="article-19424.r5">[5]</xref><xref ref-type="bibr" rid="article-19424.r21">[21]</xref> Associated clinical manifestations are primarily portal hypertension, splenomegaly, hepatic fibrosis, and cholangitis.<xref ref-type="bibr" rid="article-19424.r11">[11]</xref></p>
      </sec>
      <sec id="article-19424.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histology shows distal renal tubular and collecting duct cysts lined by columnar or cuboidal epithelium. A liver biopsy shows various degrees of diffuse fibrosis and dilated intrahepatic ducts.<xref ref-type="bibr" rid="article-19424.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-19424.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Early identification of patients with ARPKD has increased tremendously in the last few decades, with routine antenatal ultrasound usually showing very large, echogenic kidneys. Sometimes the kidneys are so enlarged they can interfere with normal vaginal delivery.</p>
        <p>Perinatal demise for the first 30 days after birth is primarily due to respiratory distress from pulmonary hypoplasia and reduced vital capacity from thoracic compression by the markedly enlarged kidneys. Usually, in the first few months, infants will have renal dysfunction and hypertension (75%), which may be severe.</p>
        <p>Failure to thrive and growth retardation is a significant concern, as nutritional status can be affected by excessively enlarged kidneys, portal hypertension, renal failure, and the possible need for peritoneal dialysis.</p>
        <p>Symptoms that develop in early childhood include urinary tract infections, gross hematuria, and renal osteopathy. Neurocognitive function in children with ARPKD is not affected.<xref ref-type="bibr" rid="article-19424.r24">[24]</xref></p>
        <p>Variable degrees of congenital hepatic fibrosis are present, which can lead to splenomegaly, thrombocytopenia, and esophageal varices with the potential for upper GI bleeding. Cholangitis is a common presentation and should be ruled out in any patient with ARPKD who presents with fever or abdominal pain.</p>
        <p>Earlier (neonatal) diagnosis is associated with more severe kidney disease, while a later presentation tends to demonstrate milder degrees of renal impairment but more severe liver disease with portal hypertension.<xref ref-type="bibr" rid="article-19424.r25">[25]</xref><xref ref-type="bibr" rid="article-19424.r26">[26]</xref><xref ref-type="bibr" rid="article-19424.r27">[27]</xref></p>
        <p>Physical examination findings may include Potter's facies, limb deformities, and other oligohydramnios-related signs. The kidneys are often markedly enlarged, and there may be splenomegaly. Potter's sequence may be present, including severe oligohydramnios, pulmonary hypoplasia, limb deformities from utero compression (eg, club feet, hip dislocations), and Potter's facies.)</p>
      </sec>
      <sec id="article-19424.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>ARPKD can present antenatally with evidence of oligohydramnios or enlarged fetal echogenic kidneys. Amniocentesis for gene karyotyping is an option if desired.<xref ref-type="bibr" rid="article-19424.r12">[12]</xref>&#x000a0;A detailed family history&#x000a0;of renal disease or unexplained perinatal loss should be taken.&#x000a0;The absence of renal findings in the&#x000a0;patient's biological parents increases the suspicion of ARPKD and prompts consideration for further genetic testing.<xref ref-type="bibr" rid="article-19424.r28">[28]</xref></p>
        <p>Laboratory testing should include kidney and liver function, electrolytes, serum albumin, coagulation studies, and a complete blood count, as thrombocytopenia from splenic sequestration is often seen, particularly with portal hypertension. Platelet count and thrombocytopenia are excellent indicators of the severity of portal hypertension (frequently underdiagnosed) in patients with ARPKD.<xref ref-type="bibr" rid="article-19424.r26">[26]</xref></p>
        <p>Neonates may not be able to produce dilute urine and may, therefore, demonstrate hyponatremia for the first few weeks immediately after birth.<xref ref-type="bibr" rid="article-19424.r29">[29]</xref>&#x000a0;Be aware that serum laboratory tests on newborns (eg, electrolytes and creatinine) will reflect maternal serum values for the first 24&#x000a0;to 48 hours after birth.</p>
        <p><bold>Ultrasonography</bold> is the preferred imaging modality, particularly in the perinatal and neonatal periods.<xref ref-type="bibr" rid="article-19424.r30">[30]</xref><xref ref-type="bibr" rid="article-19424.r31">[31]</xref>&#x000a0;Antenatal diagnosis can be made by the 24th week of gestation, although it has occasionally been identified as early as 18 weeks after conception. Ultrasound typically shows bilateral smooth, massively enlarged kidneys with loss of corticomedullary differentiation. Increased echogenicity and microcysts are typical and common.<xref ref-type="bibr" rid="article-19424.r30">[30]</xref>&#x000a0;The markedly enlarged kidneys may concentrate the bowel loops towards the midline.&#x000a0;</p>
        <p>In older children with ARPKD, ultrasound may show larger cysts and increased echogenicity from cysts arising from the distal tubules and collecting ducts, which are concentrated in the renal medulla.&#x000a0;Contrast-enhanced ultrasound can be performed but requires additional expertise.<xref ref-type="bibr" rid="article-19424.r30">[30]</xref></p>
        <p>Unlike ADPKD, total kidney volume does not necessarily correlate with renal function.<xref ref-type="bibr" rid="article-19424.r12">[12]</xref>&#x000a0;Hepatic ultrasound may demonstrate hepatomegaly, increased echogenicity, hepatic cysts, and dilatation of peripheral parenchymal and extrahepatic biliary ducts.<xref ref-type="bibr" rid="article-19424.r31">[31]</xref>&#x000a0;Biliary abnormalities will be found at some point in 70% of ARPKD patients.<xref ref-type="bibr" rid="article-19424.r26">[26]</xref></p>
        <p><bold>Magnetic resonance imaging</bold> (MRI) can be used instead as it avoids ionizing radiation and shows hepatic lesions well, but this often requires sedation, which carries its risks.<xref ref-type="bibr" rid="article-19424.r30">[30]</xref>&#x000a0;Cysts are best imaged on T2-weighted sequences.<xref ref-type="bibr" rid="article-19424.r30">[30]</xref>&#x000a0;CT and MRI scans are not necessary for a diagnosis of ARPKD but may be helpful in selected cases.&#x000a0;CT scans should be avoided when possible in children due to the radiation exposure.</p>
        <p>In older patients, CT imaging shows smooth, enlarged kidneys with a striated pattern of contrast excretion.<xref ref-type="bibr" rid="article-19424.r32">[32]</xref> The striated pattern on CT signifies a collection of contrast in dilated renal collecting tubules.</p>
        <p>The diagnosis of ARPKD is made&#x000a0;in most cases by a combination of renal ultrasound findings, clinical presentation, and the lack of a family history of kidney disease.<xref ref-type="bibr" rid="article-19424.r33">[33]</xref><xref ref-type="bibr" rid="article-19424.r34">[34]</xref>&#x000a0;</p>
        <p><bold>Genetic&#x000a0;testing</bold> is beneficial and recommended in confirming a diagnosis of ARPKD, especially if the history, clinical findings, and imaging are inconclusive, as most patients will have an identifiable gene mutation (<italic toggle="yes">PHKD1)</italic><italic toggle="yes">.</italic><xref ref-type="bibr" rid="article-19424.r19">[19]</xref><xref ref-type="bibr" rid="article-19424.r35">[35]</xref><xref ref-type="bibr" rid="article-19424.r36">[36]</xref><xref ref-type="bibr" rid="article-19424.r37">[37]</xref><xref ref-type="bibr" rid="article-19424.r38">[38]</xref><xref ref-type="bibr" rid="article-19424.r39">[39]</xref><xref ref-type="bibr" rid="article-19424.r40">[40]</xref>&#x000a0;While genetic testing is considered the "gold standard" diagnostic modality, it may miss some cases due to the large number of genetic variants.<xref ref-type="bibr" rid="article-19424.r39">[39]</xref><xref ref-type="bibr" rid="article-19424.r40">[40]</xref>&#x000a0;Overall reliability (positive predictive value) of genetic testing is reported at 80% to 85%.<xref ref-type="bibr" rid="article-19424.r8">[8]</xref><xref ref-type="bibr" rid="article-19424.r9">[9]</xref><xref ref-type="bibr" rid="article-19424.r39">[39]</xref><xref ref-type="bibr" rid="article-19424.r41">[41]</xref></p>
        <p>A definitive diagnosis confirmed by genetic testing clearly establishes a prognosis, improves clinical management, facilitates the early detection of comorbidities and complications, avoids unnecessary procedures and invasive testing, optimizes the timing and focus of follow-up evaluations, and allows proper genetic counseling for the patient and family.<xref ref-type="bibr" rid="article-19424.r19">[19]</xref></p>
        <p>Once a diagnosis of ARPKD is made, involvement of the liver should be assumed. The initial hepatic ultrasound is often routine or may show only minimal cysts. A baseline hepatic MRI can be considered. Liver chemistries are usually normal in neonates, as hepatic function is generally preserved early in life. Liver function can be followed by laboratory testing (liver enzymes, bilirubin, coagulation studies, serum albumin, and platelet count), periodic hepatic ultrasound, and MRI imaging.</p>
        <p>The first signs of congenital hepatic fibrosis are usually portal hypertension and splenomegaly, which may manifest as thrombocytopenia or gastrointestinal (GI) bleeding.<xref ref-type="bibr" rid="article-19424.r12">[12]</xref></p>
        <p><bold>Consensus guidelines </bold>suggest further surveillance imaging as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Liver and spleen ultrasound with Doppler of the portal and splenic veins monitoring for intrahepatic or extrahepatic biliary dilatation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Annual laboratory tests for complete blood counts (especially platelets) should be followed to assess for splenomegaly.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A complete abdominal ultrasound should be&#x000a0;performed on children aged 5 years with special attention to the bile ducts and spleen size. Any abnormalities should prompt referral to a pediatric hepatologist and screening for complications following the standard guidelines.<xref ref-type="bibr" rid="article-19424.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>Up to 5% of patients with&#x000a0;ADPKD&#x000a0;present in childhood, prenatally, or as neonates, making the incidence of the&#x000a0;2 polycystic kidney disorders comparable.<xref ref-type="bibr" rid="article-19424.r11">[11]</xref><xref ref-type="bibr" rid="article-19424.r19">[19]</xref>&#x000a0;Differentiating&#x000a0;ARPKD from&#x000a0;ADPKD can sometimes be challenging as the clinical presentations overlap.<xref ref-type="bibr" rid="article-19424.r3">[3]</xref><xref ref-type="bibr" rid="article-19424.r33">[33]</xref>&#x000a0;</p>
        <p>ARPKD is a more severe form of the disorder that typically appears early, usually at birth, and can often be diagnosed antenatally. The facts to consider regarding ARPKD are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>The condition is relatively rare at 1:20,000 to 40,000 live births.<xref ref-type="bibr" rid="article-19424.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Cerebral aneurysms are extremely rare.</p>
          </list-item>
          <list-item>
            <p>No specific cardiovascular anomalies are observed.</p>
          </list-item>
          <list-item>
            <p>Liver disease is always present and likely to eventually become significant or severe.<xref ref-type="bibr" rid="article-19424.r33">[33]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>No family history of renal cystic disease or kidney failure is usually present.</p>
          </list-item>
          <list-item>
            <p>Perinatal mortality is high, and end-stage kidney disease affects half of those who survive to age 20.<xref ref-type="bibr" rid="article-19424.r33">[33]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>ADPKD disease is a slower and milder form of the condition that usually demonstrates symptoms starting at about age 30.<xref ref-type="bibr" rid="article-19424.r3">[3]</xref>&#x000a0;The facts to consider regarding ADPKD are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>The disorder is relatively common at 1:400 to 1:1,000 live births.<xref ref-type="bibr" rid="article-19424.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Cerebral aneurysms may be present.</p>
          </list-item>
          <list-item>
            <p>Cardiac anomalies may be present, especially mitral valve prolapse.</p>
          </list-item>
          <list-item>
            <p>Liver cysts may be present, but not usually early, and overall liver function is not usually affected.<xref ref-type="bibr" rid="article-19424.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>A family history of hypertension and kidney disease is very likely.</p>
          </list-item>
          <list-item>
            <p>Overall life expectancy with proper treatment averages up to age 70.</p>
          </list-item>
          <list-item>
            <p>End-stage kidney disease develops in most patients starting in their 60's.<xref ref-type="bibr" rid="article-19424.r3">[3]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19424.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Perinatal management depends on the severity of the clinical manifestations and the organs involved. This involves monitoring&#x000a0;respiratory function, renal function tests, liver function tests, infant growth evaluation, blood&#x000a0;pressure monitoring, and symptomatic treatment. Cesarean delivery may be preferred if ARPKD is diagnosed antenatally due to the increased risk of dystocia from the massively enlarged fetal kidneys.<xref ref-type="bibr" rid="article-19424.r39">[39]</xref><xref ref-type="bibr" rid="article-19424.r42">[42]</xref><xref ref-type="bibr" rid="article-19424.r43">[43]</xref>&#x000a0;</p>
        <p>Nephrectomy is occasionally required for significantly enlarged kidneys compromising respiratory or gastrointestinal function but is associated with significant complications.<xref ref-type="bibr" rid="article-19424.r12">[12]</xref>&#x000a0;ARPKD patients with end-stage kidney disease who ultimately receive renal transplants can benefit from nephrectomies of their nonfunctional kidneys by making more room available for the new kidney and facilitating blood pressure control after transplantation.<xref ref-type="bibr" rid="article-19424.r5">[5]</xref>&#x000a0;</p>
        <p><bold>Initial treatment</bold> may consist of respiratory support, fluid and electrolyte management (for hyponatremia or hyperkalemia), control of hypertension, nutritional support, bicarbonate or citrate supplements for metabolic acidosis, antibiotics for infections, and peritoneal dialysis if required.<xref ref-type="bibr" rid="article-19424.r5">[5]</xref><xref ref-type="bibr" rid="article-19424.r7">[7]</xref></p>
        <p><bold>Pulmonary hypoplasia</bold> can often be managed by respiratory supportive measures such as mechanical ventilation, allowing the lungs to mature further. Pulmonary hypertension can sometimes be treated with nitrous oxide, and the use of palivizumab, a prophylactic monoclonal antibody for respiratory syncytial virus, is recommended.<xref ref-type="bibr" rid="article-19424.r33">[33]</xref>&#x000a0;Almost half of ARPKD patients diagnosed prenatally will be born with clinically significant pulmonary hypoplasia. Respiratory problems are the leading cause of death in neonates with ARPKD.</p>
        <p><bold>Significant renal failure</bold> may induce hyperkalemia, while hyponatremia is often found in neonates with ARPKD. The hyponatremia is usually transient and treated with fluid restriction.<xref ref-type="bibr" rid="article-19424.r44">[44]</xref>&#x000a0;Patients with liver disease may need supplemental bile acids, endoscopic control of varices, or a portal vein shunting procedure.&#x000a0;Renal replacement therapy, if indicated, can include hemodialysis or renal transplantation, but usually, peritoneal dialysis is preferred. Some patients may need nephrectomies to allow sufficient space for adequate peritoneal dialysis.</p>
        <p>Patients with significant renal failure may also require iron and erythropoietin therapy for the management of anemia, calcium and vitamin D supplements for bone health, phosphate binders for hyperphosphatemia, sodium bicarbonate or potassium citrate for metabolic acidosis, and medical parathyroid hormone suppression with a calcimimetic agent.&#x000a0;The use of recombinant human growth hormone appears to be safe and effective in promoting normal growth, which might otherwise be suppressed by uremia and reduced nutritional intake.<xref ref-type="bibr" rid="article-19424.r45">[45]</xref></p>
        <p>ARPKD patients who eventually receive renal transplants are at higher risk of death from cholangitis and biliary sepsis due to the required immunosuppressive drugs, which is a concern.<xref ref-type="bibr" rid="article-19424.r46">[46]</xref></p>
        <p><bold>Hypertension</bold> is often severe, requiring multiple medications for control, starting with renin-angiotensin-aldosterone system (RAAS) blockers, which are usually the first-line treatments.<xref ref-type="bibr" rid="article-19424.r7">[7]</xref>&#x000a0;Beta-blockers, calcium channel blockers, dietary salt restriction, and diuretics can be used to complement RAAS inhibitors, when necessary, to achieve adequate blood pressure control.&#x000a0;The appearance of hypertension generally precedes any clinical evidence of renal failure and will be present in 80% of children with ARPKD.<xref ref-type="bibr" rid="article-19424.r9">[9]</xref>&#x000a0;Management of hypertension is usually easier after the first year of life.<xref ref-type="bibr" rid="article-19424.r5">[5]</xref></p>
        <p>The ESCAPE trial (published in 2009) noted that children with stages 2 to 4 chronic kidney disease from all causes had improved renal function with aggressive blood pressure control.<xref ref-type="bibr" rid="article-19424.r12">[12]</xref></p>
        <p><bold>Nutritional support</bold> can be highly beneficial in patients with ARPKD, particularly during the first two years after birth.<xref ref-type="bibr" rid="article-19424.r33">[33]</xref><xref ref-type="bibr" rid="article-19424.r47">[47]</xref>&#x000a0;This is especially important in those children with significant portal hypertension and early renal failure.<xref ref-type="bibr" rid="article-19424.r33">[33]</xref><xref ref-type="bibr" rid="article-19424.r47">[47]</xref>&#x000a0;The poor feeding is primarily due to compression on the stomach and GI tract by the extremely enlarged polycystic kidneys.&#x000a0;The use of recombinant human growth hormone has been considered to promote growth and appears safe and effective in limited studies.<xref ref-type="bibr" rid="article-19424.r45">[45]</xref></p>
        <p><bold>Liver disease</bold>&#x000a0;requires rapid treatment of ascending cholangitis and may benefit from bile acid supplements, such as ursodeoxycholic acid, to help increase the natural hepatic biliary secretions and help minimize the development of cholelithiasis.<xref ref-type="bibr" rid="article-19424.r33">[33]</xref>&#x000a0;Endoscopic sclerotherapy or banding of esophageal varices may be needed in patients with progressive portal hypertension.<xref ref-type="bibr" rid="article-19424.r33">[33]</xref> In more severe cases, portal vein shunting or a liver transplant may need to be considered. Prophylactic antibiotics to help prevent ascending cholangitis are recommended by some experts.<xref ref-type="bibr" rid="article-19424.r35">[35]</xref></p>
        <p><bold>Dual organ transplants</bold> (liver and kidney), depending on the severity of portal hypertension and end-stage renal disease, have shown promising results in a&#x000a0;significant number of cases and may be a consideration in selected patients.<xref ref-type="bibr" rid="article-19424.r47">[47]</xref></p>
        <p>Currently, tolvaptan, a vasopressin receptor antagonist, is the only FDA-approved treatment for ADPKD, and several large trials with long-term follow-up have demonstrated efficacy in preserving renal function.<xref ref-type="bibr" rid="article-19424.r3">[3]</xref><xref ref-type="bibr" rid="article-19424.r48">[48]</xref><xref ref-type="bibr" rid="article-19424.r49">[49]</xref><xref ref-type="bibr" rid="article-19424.r50">[50]</xref><xref ref-type="bibr" rid="article-19424.r51">[51]</xref>&#x000a0;Ongoing clinical trials are studying tolvaptan for the possible treatment of ARPKD.<xref ref-type="bibr" rid="article-19424.r35">[35]</xref>&#x000a0;Other possible therapies are under investigation.</p>
      </sec>
      <sec id="article-19424.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for ARPKD is broad and includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>ADPKD&#x000a0;<xref ref-type="bibr" rid="article-19424.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Antenatal cytomegalovirus (CMV) infections can cause increased echogenicity of fetal kidneys on ultrasound. This can be tested by amniocentesis.<xref ref-type="bibr" rid="article-19424.r12">[12]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Autosomal dominant tubulointerstitial kidney disease, also called medullary cystic kidney disease, is an autosomal dominant disorder with a similar presentation to nephronophthisis (see below) but presents at a later age.<xref ref-type="bibr" rid="article-19424.r52">[52]</xref>&#x000a0;Interstitial and tubular fibrosis are prevalent, and several different gene mutations are associated with this condition.<xref ref-type="bibr" rid="article-19424.r52">[52]</xref><xref ref-type="bibr" rid="article-19424.r53">[53]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bardet&#x02013;Biedl, Joubert, and Meckel syndromes are also ciliopathies with presentations similar to ARPKD.<xref ref-type="bibr" rid="article-19424.r19">[19]</xref><xref ref-type="bibr" rid="article-19424.r54">[54]</xref><xref ref-type="bibr" rid="article-19424.r55">[55]</xref>&#x000a0;
<list list-type="bullet"><list-item><p>Bardet&#x02013;Biedl syndrome often presents with enlarged and hyperechogenic kidneys with a loss of corticomedullary differentiation.</p></list-item><list-item><p>Joubert and Meckel syndromes are more severe ciliopathies characterized by neurological problems and delayed development, as well as possible liver fibrosis, polydactyly, and cystic kidneys.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hereditary renal agenesis or dysplasia. One series found that patients with renal agenesis or dysplasia are much more likely to have first-degree relatives with renal malformations.<xref ref-type="bibr" rid="article-19424.r56">[56]</xref><xref ref-type="bibr" rid="article-19424.r57">[57]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hepatocyte nuclear factor 1-beta (<italic toggle="yes">HNF1&#x003b2;)</italic>&#x000a0;is a transcription factor gene regulating the expression of&#x000a0;<italic toggle="yes">PKHD1,</italic> and mutations here can cause various clinical symptoms, including renal cysts mimicking ARPKD.<xref ref-type="bibr" rid="article-19424.r58">[58]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nephronophthisis is another autosomal recessive cystic kidney disease manifesting in tubulointerstitial microcysts and renal fibrosis.<xref ref-type="bibr" rid="article-19424.r59">[59]</xref>&#x000a0;Nephronophthisis commonly causes end-stage renal disease (ESRD) in patients younger than 25.<xref ref-type="bibr" rid="article-19424.r1">[1]</xref><xref ref-type="bibr" rid="article-19424.r59">[59]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Von Hippel&#x02013;Lindau syndrome is an autosomal dominant disease caused by mutations in the tumor suppressor <italic toggle="yes">VHL</italic> gene.<xref ref-type="bibr" rid="article-19424.r60">[60]</xref> Primary symptoms are hemangioblastomas in the central nervous system and renal tumors.<xref ref-type="bibr" rid="article-19424.r60">[60]</xref> Affected people also have a high probability of renal and pancreatic cysts. The similarity in manifestations between tuberous sclerosis, von Hippel Landau, and polycystic kidney disease suggests a functional connection involving primary cilium and the mTOR signaling pathway.<xref ref-type="bibr" rid="article-19424.r60">[60]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Other rare genetic abnormalities that may present similarly to ARPKD include:&#x000a0;
<list list-type="bullet"><list-item><p>Brachymesomelia-renal syndrome</p></list-item><list-item><p>Senior-L&#x000f8;ken syndrome</p></list-item><list-item><p>Smith-Lemli-Opitz syndrome</p></list-item><list-item><p>Short-rib-polydactyly syndrome</p></list-item><list-item><p>Trisomy 13</p></list-item><list-item><p>Tuberous sclerosis&#x000a0;<xref ref-type="bibr" rid="article-19424.r19">[19]</xref><xref ref-type="bibr" rid="article-19424.r54">[54]</xref><xref ref-type="bibr" rid="article-19424.r61">[61]</xref><xref ref-type="bibr" rid="article-19424.r62">[62]</xref><xref ref-type="bibr" rid="article-19424.r63">[63]</xref><xref ref-type="bibr" rid="article-19424.r64">[64]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19424.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis depends on the severity of the pulmonary, hepatic, and renal disease. Neonates born with severe renal disease may not survive&#x000a0;due&#x000a0;to pulmonary hypoplasia and insufficiency, which may occur in up to 40% of cases.<xref ref-type="bibr" rid="article-19424.r8">[8]</xref><xref ref-type="bibr" rid="article-19424.r9">[9]</xref></p>
        <p>Neonatal mortality has improved due to advances in neonatal care but remains at about 20%.<xref ref-type="bibr" rid="article-19424.r10">[10]</xref> Those who survive the neonatal period have 10-year survival rates estimated at 82% but often develop progressive renal failure, hypertension, hepatic fibrosis, portal hypertension, and end-stage renal disease.<xref ref-type="bibr" rid="article-19424.r9">[9]</xref><xref ref-type="bibr" rid="article-19424.r39">[39]</xref>&#x000a0;Other reports suggest that over 90% of those who survive the neonatal period will survive to age 20.</p>
        <p>The liver disease in ARPKD is relatively mild in neonates and early childhood, but the severity of the hepatic dysfunction progresses with age. These children develop&#x000a0;features of portal hypertension because of&#x000a0;chronic hepatic fibrosis. However, as portal hypertension and variceal bleeding are not generally life-threatening if properly managed, many of these patients survive up to&#x000a0;middle age. Patients with ARPKD older than 40 have a slightly increased risk of hepatic tumors, especially cholangiocarcinoma.<xref ref-type="bibr" rid="article-19424.r11">[11]</xref></p>
      </sec>
      <sec id="article-19424.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications associated with&#x000a0;ARPKD include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Azotemia</p>
          </list-item>
          <list-item>
            <p>Cholangitis</p>
          </list-item>
          <list-item>
            <p>Congenital hepatic fibrosis</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal bleeding</p>
          </list-item>
          <list-item>
            <p>Hypertension, often severe</p>
          </list-item>
          <list-item>
            <p>Increased risk for ascending cholangitis</p>
          </list-item>
          <list-item>
            <p>Large bilateral flank masses</p>
          </list-item>
          <list-item>
            <p>Liver failure and cirrhosis</p>
          </list-item>
          <list-item>
            <p>Malabsorption of fat-soluble vitamins</p>
          </list-item>
          <list-item>
            <p>Poor growth, feeding, and nutrition</p>
          </list-item>
          <list-item>
            <p>Progressive portal hypertension with esophageal and gastric varices, splenomegaly, and GI bleeds</p>
          </list-item>
          <list-item>
            <p>Progressive renal failure</p>
          </list-item>
          <list-item>
            <p>Renal osteopathy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Respiratory distress due to pulmonary hypoplasia and limited diaphragmatic mobility due to the massively enlarged kidneys</p>
          </list-item>
          <list-item>
            <p>Splenomegaly (present in about 60% of patients)</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19424.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The risk to parents of having another baby with ARPKD after having had one child with the disorder&#x000a0;is 25% due to its autosomal recessive inheritance pattern.<xref ref-type="bibr" rid="article-19424.r19">[19]</xref>&#x000a0;With gene penetration at 1:70, the estimated risk of ARPKD is as follows:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Children of patients with ARPKD: 1:140.</p>
          </list-item>
          <list-item>
            <p>Children of healthy siblings: 1:420.</p>
          </list-item>
          <list-item>
            <p>Children of healthy aunts and uncles: 1:560.<xref ref-type="bibr" rid="article-19424.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>Any diagnosis of ARPKD should prompt evaluation in first-degree relatives, especially siblings who&#x000a0;have a 66% risk of being a carrier for ARPKD, even if apparently healthy.<xref ref-type="bibr" rid="article-19424.r19">[19]</xref>&#x000a0;Patients with ARPKD or a family history of this genetic disorder should be made aware of the risk in future children, and amniocentesis can be offered to patients who request this service.</p>
        <p>Patients and their families must receive education regarding their condition, likely disease progression, complications, and management options, as well as genetic testing and appropriate counseling.&#x000a0;Contact sports are not recommended for patients with ARPKD. Social support to patients and families during treatment and management is paramount.</p>
      </sec>
      <sec id="article-19424.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind regarding ARPKD include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Renal ultrasounds of both parents can be helpful and are suggested as well as in siblings.</p>
          </list-item>
          <list-item>
            <p>Genetic testing should be considered in siblings and other appropriate family members so proper genetic counseling can be made available. Such&#x000a0;counseling should be involved in all cases where ARPKD has been diagnosed.</p>
          </list-item>
          <list-item>
            <p>Although&#x000a0;ARPKD and&#x000a0;ADPKD may seem far apart clinically, they can overlap. In those cases, evidence of hepatic involvement, family history, and particularly genetic testing are the best ways to differentiate them.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19424.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with&#x000a0;ARPKD are at high&#x000a0;risk of ESRD. Early identification and management of patients with ARPKD are imperative in reducing morbidity and mortality.&#x000a0;The care of patients with ARPKD can begin antenatally with the detection of oligohydramnios or abnormalities of the renal system. Initial complications include pulmonary hypoplasia, which may necessitate mechanical ventilation and monitoring in a neonatal intensive care unit. Liver involvement is always present and frequently becomes symptomatic as patients mature.</p>
        <p>ARPKD necessitates a collaborative approach among healthcare professionals to ensure patient-centered care and improve overall outcomes. Obstetricians, maternal-fetal medicine specialists, pediatric nephrologists, adult nephrologists, urologists, pediatric urologists, critical care physicians, gastroenterologists, hepatologists, advanced practitioners, nurses, pharmacists, and the many other health professionals involved in the care of these complex patients should possess the essential clinical skills and knowledge to diagnose and manage ARPKD.&#x000a0;</p>
        <p>This includes expertise in recognizing the varied clinical presentations and understanding the nuances of diagnostic techniques such as renal ultrasound, MRI, and abdominal imaging. Patient and caregiver education about&#x000a0;the genetic component of ARPKD, the natural progression of associated renal disease, and common renal and gastrointestinal&#x000a0;symptoms are essential to prevent morbidity.</p>
        <p>Effective interprofessional communication is paramount, allowing seamless information exchange and collaborative decision-making among the team members. Care coordination plays a pivotal role in ensuring that the patient's journey from diagnosis to treatment and follow-up is well-managed, minimizing errors and enhancing patient safety. By embracing these principles of skill, strategy, interprofessional communication, and care coordination, healthcare professionals can deliver optimal patient-centered care, ultimately improving patient outcomes and enhancing team performance in the management of ARPKD.</p>
      </sec>
      <sec id="article-19424.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19424&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19424">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/autosomal-recessive-polycystic-kidney-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19424">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19424/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19424">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-19424.s17">
        <fig id="article-19424.image.f1" position="float" orientation="portrait">
          <caption>
            <p>ARPKD in a 6-month -old girl. Enalrged and ecogenic kidney with cysts. Contributed by Surabhi Subramanian .</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Picture1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-19424.s18">
        <fig id="article-19424.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Polycystic kidney disease Contributed by Sunil Munakomi, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="polycustic__kidney" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-19424.s19">
        <title>References</title>
        <ref id="article-19424.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Goksu</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Khattar</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Renal Cystic Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">32119391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Autosomal dominant polycystic kidney disease: the last 3 years.</article-title>
            <source>Kidney Int</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>76</volume>
            <issue>2</issue>
            <fpage>149</fpage>
            <page-range>149-68</page-range>
            <pub-id pub-id-type="pmid">19455193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mahboob</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rout</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Bokhari</surname>
                <given-names>SRA</given-names>
              </name>
            </person-group>
            <chapter-title>Autosomal Dominant Polycystic Kidney Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30422529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Galliani</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Musulman-Mroczek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Spear</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Guillot</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Diffuse renal cystic disease in children: morphologic and genetic correlations.</article-title>
            <source>Pediatr Nephrol</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>173</fpage>
            <page-range>173-82</page-range>
            <pub-id pub-id-type="pmid">9630032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Horie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>DJM</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>Polycystic kidney disease.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2018</year>
            <month>Dec</month>
            <day>06</day>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <pub-id pub-id-type="pmid">30523303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goggolidou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The genetics of Autosomal Recessive Polycystic Kidney Disease (ARPKD).</article-title>
            <source>Biochim Biophys Acta Mol Basis Dis</source>
            <year>2022</year>
            <month>Apr</month>
            <day>01</day>
            <volume>1868</volume>
            <issue>4</issue>
            <fpage>166348</fpage>
            <pub-id pub-id-type="pmid">35032595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liebau</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Early clinical management of autosomal recessive polycystic kidney disease.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>36</volume>
            <issue>11</issue>
            <fpage>3561</fpage>
            <page-range>3561-3570</page-range>
            <pub-id pub-id-type="pmid">33594464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Desmond</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Autosomal recessive polycystic kidney disease: the clinical experience in North America.</article-title>
            <source>Pediatrics</source>
            <year>2003</year>
            <month>May</month>
            <volume>111</volume>
            <issue>5 Pt 1</issue>
            <fpage>1072</fpage>
            <page-range>1072-80</page-range>
            <pub-id pub-id-type="pmid">12728091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Senderek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Windelen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>K&#x000fc;pper</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Middeldorf</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dornia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rudnik-Sch&#x000f6;neborn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Konrad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Seeman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Neuhaus</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Vester</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kirfel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>B&#x000fc;ttner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zerres</surname>
                <given-names>K</given-names>
              </name>
              <collab>APN (Arbeitsgemeinschaft f&#x000fc;r P&#x000e4;diatrische Nephrologie)</collab>
            </person-group>
            <article-title>Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD).</article-title>
            <source>Kidney Int</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>829</fpage>
            <page-range>829-48</page-range>
            <pub-id pub-id-type="pmid">15698423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alzarka</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morizono</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bollman</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Design and Implementation of the Hepatorenal Fibrocystic Disease Core Center Clinical Database: A Centralized Resource for Characterizing Autosomal Recessive Polycystic Kidney Disease and Other Hepatorenal Fibrocystic Diseases.</article-title>
            <source>Front Pediatr</source>
            <year>2017</year>
            <volume>5</volume>
            <fpage>80</fpage>
            <pub-id pub-id-type="pmid">28473971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cordido</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vizoso-Gonzalez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garcia-Gonzalez</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Molecular Pathophysiology of Autosomal Recessive Polycystic Kidney Disease.</article-title>
            <source>Int J Mol Sci</source>
            <year>2021</year>
            <month>Jun</month>
            <day>17</day>
            <volume>22</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">34204582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bockenhauer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cadnapaphornchai</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dell</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Kerecuk</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liebau</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Alonso-Peclet</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Shneider</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Emre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kamath</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Moise</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eichenwald</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Wilkins-Haug</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gunay-Aygun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Hartung</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Streisand</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moxey-Mims</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference.</article-title>
            <source>J Pediatr</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>165</volume>
            <issue>3</issue>
            <fpage>611</fpage>
            <page-range>611-7</page-range>
            <pub-id pub-id-type="pmid">25015577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Senderek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>K&#x000fc;pper</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dornia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Windelen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eggermann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rudnik-Sch&#x000f6;neborn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kirfel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Furu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Onuchic</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Rossetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Somlo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Germino</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>B&#x000fc;ttner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zerres</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD).</article-title>
            <source>Hum Mutat</source>
            <year>2004</year>
            <month>May</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>453</fpage>
            <page-range>453-63</page-range>
            <pub-id pub-id-type="pmid">15108277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rossetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sneddon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kubly</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bacallao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ishibashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Milliner</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein.</article-title>
            <source>Nat Genet</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-69</page-range>
            <pub-id pub-id-type="pmid">11919560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Onuchic</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Furu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nagasawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Eggermann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Senderek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Esquivel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zeltner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rudnik-Sch&#x000f6;neborn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mrug</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Avner</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Zerres</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Somlo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Germino</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats.</article-title>
            <source>Am J Hum Genet</source>
            <year>2002</year>
            <month>May</month>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>1305</fpage>
            <page-range>1305-17</page-range>
            <pub-id pub-id-type="pmid">11898128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menezes</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nagasawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Da Silva</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Somlo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Germino</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Onuchic</surname>
                <given-names>LF</given-names>
              </name>
            </person-group>
            <article-title>Polyductin, the PKHD1 gene product, comprises isoforms expressed in plasma membrane, primary cilium, and cytoplasm.</article-title>
            <source>Kidney Int</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>66</volume>
            <issue>4</issue>
            <fpage>1345</fpage>
            <page-range>1345-55</page-range>
            <pub-id pub-id-type="pmid">15458427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Traubici</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Daneman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>High-resolution renal sonography in children with autosomal recessive polycystic kidney disease.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2005</year>
            <month>May</month>
            <volume>184</volume>
            <issue>5</issue>
            <fpage>1630</fpage>
            <page-range>1630-3</page-range>
            <pub-id pub-id-type="pmid">15855129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zerres</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Early manifestations of polycystic kidney disease.</article-title>
            <source>Lancet</source>
            <year>2007</year>
            <month>Jun</month>
            <day>30</day>
            <volume>369</volume>
            <issue>9580</issue>
            <fpage>2157</fpage>
            <pub-id pub-id-type="pmid">17604790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Genetics of Autosomal Recessive Polycystic Kidney Disease and Its Differential Diagnoses.</article-title>
            <source>Front Pediatr</source>
            <year>2017</year>
            <volume>5</volume>
            <fpage>221</fpage>
            <pub-id pub-id-type="pmid">29479522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Masyuk</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Punyashthiti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bacallao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Torra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>LaRusso</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia.</article-title>
            <source>Hum Mol Genet</source>
            <year>2003</year>
            <month>Oct</month>
            <day>15</day>
            <volume>12</volume>
            <issue>20</issue>
            <fpage>2703</fpage>
            <page-range>2703-10</page-range>
            <pub-id pub-id-type="pmid">12925574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kyalwazi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kudaravalli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Caroli Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>8</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">30020679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richards</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Yoder</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Woychik</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Avner</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease.</article-title>
            <source>J Clin Invest</source>
            <year>1998</year>
            <month>Mar</month>
            <day>01</day>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>935</fpage>
            <page-range>935-9</page-range>
            <pub-id pub-id-type="pmid">9486961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinez</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Grantham</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Polycystic kidney disease: etiology, pathogenesis, and treatment.</article-title>
            <source>Dis Mon</source>
            <year>1995</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>693</fpage>
            <page-range>693-765</page-range>
            <pub-id pub-id-type="pmid">7587886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartung</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Matheson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lande</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Dell</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Gerson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Warady</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Furth</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Neurocognition in children with autosomal recessive polycystic kidney disease in the CKiD cohort study.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>1957</fpage>
            <page-range>1957-65</page-range>
            <pub-id pub-id-type="pmid">24828609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaikewitz</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Autosomal recessive polycystic kidney disease: issues regarding the variability of clinical presentation.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>1993</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>12</issue>
            <fpage>1858</fpage>
            <page-range>1858-62</page-range>
            <pub-id pub-id-type="pmid">8338916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunay-Aygun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Font-Montgomery</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lukose</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tuchman Gerstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piwnica-Worms</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Choyke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Daryanani</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Turkbey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bernardini</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sincan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Roque</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Douek</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Graf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huizing</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease.</article-title>
            <source>Gastroenterology</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>144</volume>
            <issue>1</issue>
            <fpage>112</fpage>
            <page-range>112-121.e2</page-range>
            <pub-id pub-id-type="pmid">23041322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zerres</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rudnik-Sch&#x000f6;neborn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Steinkamm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>M&#x000fc;cher</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Autosomal recessive polycystic kidney disease.</article-title>
            <source>J Mol Med (Berl)</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>76</volume>
            <issue>5</issue>
            <fpage>303</fpage>
            <page-range>303-9</page-range>
            <pub-id pub-id-type="pmid">9587064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sweeney</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Avner</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of childhood polycystic kidney diseases: new insights into disease-specific therapy.</article-title>
            <source>Pediatr Res</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>75</volume>
            <issue>1-2</issue>
            <fpage>148</fpage>
            <page-range>148-57</page-range>
            <pub-id pub-id-type="pmid">24336431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Fay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dillon</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Autosomal recessive polycystic kidney disease.</article-title>
            <source>Pediatr Nephrol</source>
            <year>1989</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-9</page-range>
            <pub-id pub-id-type="pmid">2702087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gimpel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Avni</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Breysem</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Burgmaier</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Caroli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cetiner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haffner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hartung</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Franke</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liebau</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Mekahli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>ACM</given-names>
              </name>
              <name>
                <surname>Pape</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Titieni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Torra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Winyard</surname>
                <given-names>PJD</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Imaging of Kidney Cysts and Cystic Kidney Diseases in Children: An International Working Group Consensus Statement.</article-title>
            <source>Radiology</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>290</volume>
            <issue>3</issue>
            <fpage>769</fpage>
            <page-range>769-782</page-range>
            <pub-id pub-id-type="pmid">30599104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turkbey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ocak</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Daryanani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Font-Montgomery</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lukose</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tuchman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Choyke</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Gunay-Aygun</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF).</article-title>
            <source>Pediatr Radiol</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>100</fpage>
            <page-range>100-11</page-range>
            <pub-id pub-id-type="pmid">19089418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gleason</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>McAlister</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Kissane</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cystic disease of the kidneys in children.</article-title>
            <source>Am J Roentgenol Radium Ther Nucl Med</source>
            <year>1967</year>
            <month>May</month>
            <volume>100</volume>
            <issue>1</issue>
            <fpage>135</fpage>
            <page-range>135-46</page-range>
            <pub-id pub-id-type="pmid">4960727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Burgmaier</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gimpel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liebau</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Autosomal Recessive Polycystic Kidney Disease&#x000a0;&#x02013;&#x000a0;<italic>PKHD1</italic></chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2001</year>
            <month>7</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">20301501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoyer</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>Clinical manifestations of autosomal recessive polycystic kidney disease.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>186</fpage>
            <page-range>186-92</page-range>
            <pub-id pub-id-type="pmid">25689455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mekahli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liebau</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Cadnapaphornchai</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Greenbaum</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Litwin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seeman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease.</article-title>
            <source>BMC Nephrol</source>
            <year>2023</year>
            <month>Feb</month>
            <day>13</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <pub-id pub-id-type="pmid">36782137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edrees</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Athar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Allaf</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Taher</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bouazzaoui</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Harbi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Safar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Al-Edressi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alansary</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Anazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Altayeb</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Abduljaleel</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Next-generation sequencing for molecular diagnosis of autosomal recessive polycystic kidney disease.</article-title>
            <source>Gene</source>
            <year>2016</year>
            <month>Oct</month>
            <day>10</day>
            <volume>591</volume>
            <issue>1</issue>
            <fpage>214</fpage>
            <page-range>214-226</page-range>
            <pub-id pub-id-type="pmid">27401137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melchionda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Palladino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Castellana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benetti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Bonis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zelante</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bisceglia</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Expanding the mutation spectrum in 130 probands with ARPKD: identification of 62 novel PKHD1 mutations by sanger sequencing and MLPA analysis.</article-title>
            <source>J Hum Genet</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>61</volume>
            <issue>9</issue>
            <fpage>811</fpage>
            <page-range>811-21</page-range>
            <pub-id pub-id-type="pmid">27225849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sieben</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Schauer</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Genetic Spectrum of Polycystic Kidney and Liver Diseases and the Resulting Phenotypes.</article-title>
            <source>Adv Kidney Dis Health</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>397</fpage>
            <page-range>397-406</page-range>
            <pub-id pub-id-type="pmid">38097330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Society for Maternal-Fetal Medicine (SMFM)</collab>
              <name>
                <surname>Swanson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Autosomal recessive polycystic kidney disease.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>225</volume>
            <issue>5</issue>
            <fpage>B7</fpage>
            <page-range>B7-B8</page-range>
            <pub-id pub-id-type="pmid">34507795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wicher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Obrycki</surname>
                <given-names>&#x00141;</given-names>
              </name>
              <name>
                <surname>Jankowska</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Autosomal Recessive Polycystic Kidney Disease-The Clinical Aspects and Diagnostic Challenges.</article-title>
            <source>J Pediatr Genet</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">33552631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Senderek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dornia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>K&#x000fc;pper</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eggermann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rudnik-Sch&#x000f6;neborn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kirfel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>B&#x000fc;ttner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zerres</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>PKHD1 mutations in families requesting prenatal diagnosis for autosomal recessive polycystic kidney disease (ARPKD).</article-title>
            <source>Hum Mutat</source>
            <year>2004</year>
            <month>May</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>487</fpage>
            <page-range>487-95</page-range>
            <pub-id pub-id-type="pmid">15108281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dukic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schaffelder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schaible</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>S&#x000fc;tterlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siemer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Massive increase of foetal abdominal circumference due to hereditary polycystic kidney disease].</article-title>
            <source>Z Geburtshilfe Neonatol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>214</volume>
            <issue>3</issue>
            <fpage>119</fpage>
            <page-range>119-22</page-range>
            <pub-id pub-id-type="pmid">20574939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Delco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parvex</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hanquinet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fokstuen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martinez de Tejada</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Eperon</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Management of delivery of a fetus with autosomal recessive polycystic kidney disease: a case report of abdominal dystocia and review of the literature.</article-title>
            <source>J Med Case Rep</source>
            <year>2019</year>
            <month>Dec</month>
            <day>12</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>366</fpage>
            <pub-id pub-id-type="pmid">31829256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartung</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects.</article-title>
            <source>Pediatrics</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>134</volume>
            <issue>3</issue>
            <fpage>e833</fpage>
            <page-range>e833-45</page-range>
            <pub-id pub-id-type="pmid">25113295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lilova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Recombinant human growth hormone therapy in autosomal recessive polycystic kidney disease.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-61</page-range>
            <pub-id pub-id-type="pmid">12488992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hupertz</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Avner</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Survival of childhood polycystic kidney disease following renal transplantation: the impact of advanced hepatobiliary disease.</article-title>
            <source>Pediatr Transplant</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>364</fpage>
            <page-range>364-9</page-range>
            <pub-id pub-id-type="pmid">14738296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Telega</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cronin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Avner</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>New approaches to the autosomal recessive polycystic kidney disease patient with dual kidney-liver complications.</article-title>
            <source>Pediatr Transplant</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>328</fpage>
            <page-range>328-35</page-range>
            <pub-id pub-id-type="pmid">23593929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>RU</given-names>
              </name>
              <name>
                <surname>Messchendorp</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Birn</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Capasso</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cornec-Le Gall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Devuyst</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>van Eerde</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guirchoun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hoorn</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Knoers</surname>
                <given-names>NVAM</given-names>
              </name>
              <name>
                <surname>Korst</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mekahli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Le Meur</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nijenhuis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>ACM</given-names>
              </name>
              <name>
                <surname>Sayer</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Servais</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Torra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Gansevoort</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2022</year>
            <month>Apr</month>
            <day>25</day>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>825</fpage>
            <page-range>825-839</page-range>
            <pub-id pub-id-type="pmid">35134221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacquaniti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Tolvaptan and autosomal dominant polycystic kidney disease in the adult: let's give time to the "TEMPO" trial (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes)].</article-title>
            <source>G Ital Nefrol</source>
            <year>2013</year>
            <season>Jan-Feb</season>
            <volume>30</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">25083527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Higashihara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Devuyst</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Gansevoort</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Grantham</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Ouyang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blais</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Czerwiec</surname>
                <given-names>FS</given-names>
              </name>
              <collab>TEMPO 3:4 Trial Investigators</collab>
            </person-group>
            <article-title>Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2016</year>
            <month>May</month>
            <day>06</day>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>803</fpage>
            <page-range>803-811</page-range>
            <pub-id pub-id-type="pmid">26912543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chebib</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Garbinsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nunna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oberdhan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies.</article-title>
            <source>Kidney Med</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>100639</fpage>
            <pub-id pub-id-type="pmid">37250503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r52">
          <label>52</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shamam</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <chapter-title>Autosomal Dominant Tubulointerstitial Kidney Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">33760469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r53">
          <label>53</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Garfield</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Medullary Sponge Kidney</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29262095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van De Weghe</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The Joubert-Meckel-Nephronophthisis Spectrum of Ciliopathies.</article-title>
            <source>Annu Rev Genomics Hum Genet</source>
            <year>2022</year>
            <month>Aug</month>
            <day>31</day>
            <volume>23</volume>
            <fpage>301</fpage>
            <page-range>301-329</page-range>
            <pub-id pub-id-type="pmid">35655331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spahiu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Behluli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Graj&#x000e7;evci-Uka</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Liehr</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Temaj</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Joubert syndrome: Molecular basis and treatment.</article-title>
            <source>J Mother Child</source>
            <year>2022</year>
            <month>Mar</month>
            <day>01</day>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>118</fpage>
            <page-range>118-123</page-range>
            <pub-id pub-id-type="pmid">36803942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodriguez</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Congenital Anomalies of the Kidney and the Urinary Tract (CAKUT).</article-title>
            <source>Fetal Pediatr Pathol</source>
            <year>2014</year>
            <season>Oct-Dec</season>
            <volume>33</volume>
            <issue>5-6</issue>
            <fpage>293</fpage>
            <page-range>293-320</page-range>
            <pub-id pub-id-type="pmid">25313840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Meckel syndrome: genetics, perinatal findings, and differential diagnosis.</article-title>
            <source>Taiwan J Obstet Gynecol</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-14</page-range>
            <pub-id pub-id-type="pmid">17389183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verhave</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bech</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Wetzels</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Nijenhuis</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Hepatocyte Nuclear Factor 1&#x003b2;-Associated Kidney Disease: More than Renal Cysts and Diabetes.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>345</fpage>
            <page-range>345-53</page-range>
            <pub-id pub-id-type="pmid">26319241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salomon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saunier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niaudet</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Nephronophthisis.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>12</issue>
            <fpage>2333</fpage>
            <page-range>2333-44</page-range>
            <pub-id pub-id-type="pmid">18607645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r60">
          <label>60</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mikhail</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <chapter-title>Von Hippel-Lindau Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29083737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r61">
          <label>61</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Noriega</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Siddik</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <chapter-title>Trisomy 13</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">32644517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r62">
          <label>62</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rout</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zamora</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <chapter-title>Tuberous Sclerosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">30860727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Cheong</surname>
                <given-names>HI</given-names>
              </name>
            </person-group>
            <article-title>Hepatorenal fibrocystic diseases in children.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-9</page-range>
            <pub-id pub-id-type="pmid">26260382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19424.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunay-Aygun</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Liver and kidney disease in ciliopathies.</article-title>
            <source>Am J Med Genet C Semin Med Genet</source>
            <year>2009</year>
            <month>Nov</month>
            <day>15</day>
            <volume>151C</volume>
            <issue>4</issue>
            <fpage>296</fpage>
            <page-range>296-306</page-range>
            <pub-id pub-id-type="pmid">19876928</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
